12:12 AM EDT, 10/15/2026 (MT Newswires) -- Lakefront Biotherapeutics (LKFT.AS) completed the transfer of its early-stage cell therapy pipeline to Belgium-based biotechnology company Armed Cell Therapeutics for an upfront payment of 8 million euros. The Amsterdam-listed biotechnology company could receive up to $230 million in milestone payments and a low-single-digit royalty, according to a Wednesday release. The transaction "substantially" wraps up Lakefront's plan to wind down its cell therapy activities. Armed Cell will independently proceed with the sold preclinical assets, comprising multi-targeting and armed CAR-T constructs for the prevention of cancer treatment resistance.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.